How strongly a vaccine protects you against the new coronavirus variants is a question we all mostly ask doctors or experts. Whether we need a booster dose or not?
Scientists collected blood samples from a number of nurses and doctors throughout the pandemic. Now they have come up with an answer.
Scientists using the neutralising antibodies checked the likelihood of coronavirus infection in the patients.
Also, there is considerable debate about how many booster doses are sufficient to combat the coronavirus variants.
A recent population study from Public Health England shows, two doses of either the Pfizer or AstraZeneca provides high levels of protection against the delta variant. The (B16172) is the new variant of concern for the world. This would suggest that booster doses are not needed – at least not initially.
In the face of this debate, fresh data suggests that an additional vaccine dose would likely generate gains in levels of immunity, especially against variants of concern.
Therefore, giving an extra dose might be crucial for reducing coronavirus infection. Approval to Pharmaceutical major Bharat Biotech was given to carry out mid-to late-stage trials of their nasal COVID-19 vaccine candidate.
“This is the first of its kind Covid-19 jab to undergo human clinical trials in India,” as per the ministry. After conducting trials in the early stage of the candidate vaccine BBV154 in subjects between the ages of 18 to 60 years, it was approved. As per the company, the vaccine doses given to healthy volunteers were well tolerated.
Moreover, in July 2021, Bharat Biotech also vowed to provide more than 500 million Covaxin doses to the government.
ALSO READ | 5 Amazing Skincare Serums For All Skin Types And Concerns